PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, Éric Barret, Jean‐Baptiste Beauval, L. Brureau, G. Créhange, G. Fiard, G. Fromont, Mathieu Gauthé, A. Ruffion, Raphaële Renard‐Penna, Romain Mathiéu, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard, Guilhem Roubaud
Abstract
Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.